✦ LIBER ✦
A multicenter, nonrandomized, open-label, single-arm phase 2 trial of dovitinib (TKI258) as second-line therapy in patients with fibroblast growth factor receptor 2-mutated or wild-type advanced and/or metastatic endometrial cancer
✍ Scribed by G. Konecny; N. Finkler; P. Lee; A. Yovine; A. Liu; P. Sen; M. Squires; A. Kay
- Book ID
- 113963747
- Publisher
- Elsevier Science
- Year
- 2012
- Tongue
- English
- Weight
- 59 KB
- Volume
- 125
- Category
- Article
- ISSN
- 0090-8258
No coin nor oath required. For personal study only.